Pharma BD Deal Intelligence

Baxalta Incorporated / Sigma-Tau Finanziaria S.p.A. (Oncaspar portfolio)

2015 · Asset Purchase · $900M · Complete

Announcement Sentiment

Strongly positive

Baxter BioScience (which spun off as Baxalta in July 2015) acquired the Oncaspar portfolio from Sigma-Tau for approximately $900M, including Oncaspar (pegaspargase), the investigational biologic calaspargase pegol, and global commercial resources. Closed July 23, 2015.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced May 12, 2015
Closed Jul 23, 2015
Deal value $900M
Deal type Asset Purchase
Therapeutic area Acute lymphoblastic leukemia (ALL)
Indications Acute lymphoblastic leukemia (ALL)
Key assets Oncaspar (pegaspargase); calaspargase pegol
Mechanism Pegylated L-asparaginase enzyme therapy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals